Illumina selected to help bring precision medicine into everyday healthcare in Singapore

Original HTML

SG-INSIGHT study will extend whole-genome sequencing to nearly 1 in 10 Singapore residents, generating evidence to inform how precision medicine could be implemented in Singapore's healthcare system

SINGAPORE, Nov. 2, 2026 /PRNewswire/ -- Illumina, Inc. (Nasdaq: ILMN) today announced it has been selected to provide whole-genome sequencing services for the SG-INSIGHT study, a cohort under Phase III of Singapore's National Precision Medicine (NPM) programme. Expected to include approximately one in 10 Singapore residents, or around 450,000 individuals, the study is designed to generate evidence from genomic and health data to help inform preventive approaches to healthcare.

The study marks an important and planned transition from studying genomics primarily in healthy volunteers to studying those with a broad range of medical conditions. By connecting genomic information with real-world health data, SG-INSIGHT aims to better understand disease and treatment responses, support the responsible introduction of genetic screening in Singapore's public healthcare system, and help healthcare become more tailored to individuals over time.

"Singapore is showing what the future of precision medicine can look like at national scale," said Jacob Thaysen, Chief Executive Officer of Illumina. "By bringing genomic information closer to everyday healthcare, this programme has the potential to advance understanding of disease, generate evidence that support more informed care decisions, and ultimately move healthcare toward earlier, more precise intervention. We are proud to bring Illumina's technology, expertise and longstanding presence in Singapore to help make that vision possible."

"Phase III builds on nearly a decade of precision medicine in Singapore," said Professor Patrick Tan, Executive Director of PRECISE. "By extending the programme to patients across the public healthcare system, SG-INSIGHT aims to deepen understanding of how genetic, lifestyle and environmental factors are associated with health and disease. Phase III reflects Singapore's ambition to build a trusted and sustainable precision health ecosystem grounded in the needs and diversity of its population."

Illumina will perform the sequencing in Singapore through its local genomics facility where scientific, laboratory and bioinformatics teams will oversee sample preparation, sequencing, and genomic data analysis. Co-located with Illumina's manufacturing and R&D operations, the facility will seek the necessary accreditation and comply with Singapore's Healthcare Services Act 2020 (HCSA), strengthening its commitment to quality, safety, regulatory compliance and biomedical innovation.

Illumina's selection for the SG-INSIGHT Study was awarded through an international competitive tender. It builds on an existing multi-year engagement, through which Illumina supported the successful implementation and delivery of NPM Phase II, PRECISE-SG100K, covering more than 100,000 genomes from healthy volunteers.

"For nearly two decades, Singapore has been one of Illumina's most important centres for innovation, manufacturing and talent in Asia Pacific," said Nilesh Shah, Head of Region, Asia Pacific, Illumina. "Our long-standing relationship with PRECISE represents the next chapter in that commitment - combining Singapore's leadership in precision health with Illumina's local genomic capabilities and regional expertise. We remain committed to investing in the people, technology and partnerships that can help advance genomics responsibly in Singapore and across the region."

Illumina established its presence in Singapore in 2008. Today, Singapore serves as the company's Asia Pacific regional headquarters and one of its largest hubs outside the United States, with more than 1,700 employees across three locations. Illumina operations in Singapore encompass commercial operations, manufacturing, and R&D, supporting global research and innovation across sequencing platforms, software, and emerging technologies.

About PRECISE

Precision Health Research, Singapore (PRECISE) is the national central entity coordinating Singapore's multi-phase National Precision Medicine (NPM) programme. Established to drive a whole-of-Singapore effort, PRECISE works with research, clinical and industry partners to generate insights into Asian genomics and translate these into better health outcomes and economic opportunities.

PRECISE is a programme of the Consortium for Clinical Research and Innovation, Singapore. NPM Phase II is supported by the National Research Foundation, Singapore (NRF) under the White Space funding (MOH-000588 and MOH-001264) and administered by the Singapore Ministry of Health (MOH) through the National Medical Research Council (NMRC) Office, MOH Holdings Pte Ltd. NPM Phase III is supported by the Singapore MOH through the NMRC Office, MOH Holdings Pte Ltd under the NMRC NPM Phase III Funding Initiative (MOH-001734).

About Illumina

Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit illumina.com and connect with us on X, Facebook, LinkedIn, Instagram, TikTok, and YouTube.

Contacts

Investors:

Illumina Investor Relations

858-291-6421

[email protected]

Media:

Christine Douglass

[email protected]

SOURCE Illumina, Inc.

Share this article

Class (B2B/B2C)

B2B

Ingest Status

Need Review

Dedupe hash

prn_302927093

Press Eligible

Yes

Press Eligible Reason

QA FAIL (need review): The target contains a factual claim not present in the source: 'Contract value was not disclosed.' The source does not mention contract value or its disclosure status.

Source Name

Unknown Company

Original Summary

<p>SG-INSIGHT study will extend whole-genome sequencing to nearly 1 in 10 Singapore residents, generating evidence to inform how precision medicine could be implemented in Singapore's healthcare system SINGAPORE, Nov. 2, 2026 /PRNewswire/ -- Illumina, Inc. (Nasdaq: ILMN) today announced it...</p>

Original Link

Original Source

Image URL

https://content.prnewswire.com/images/prn_facebook_sharing_logo.jpg

Generated Article_json

{"target_audience": "b2b", "is_medical": true, "ai_generated_title": "Illumina wins tender to sequence 450,000 Singaporeans in SG-INSIGHT", "body_html": "<p><strong>SINGAPORE -- [CURRENT_DATE] --</strong> Illumina (Nasdaq: ILMN) has been selected to provide whole-genome sequencing for SG-INSIGHT, a study expected to cover about 450,000 people, roughly one in 10 Singapore residents. The cohort sits under Phase III of Singapore's National Precision Medicine (NPM) programme.</p><h5>Illumina won the SG-INSIGHT contract through an international competitive tender</h5><p>The award builds on an existing multi-year engagement. Illumina supported delivery of NPM Phase II, PRECISE-SG100K, which covered more than 100,000 genomes from healthy volunteers. Contract value was not disclosed.</p><h5>Phase III moves from healthy volunteers to patients with a broad range of conditions</h5><p>SG-INSIGHT will link genomic data with real-world health data. Its stated aims are to improve understanding of disease and treatment responses and to support the responsible introduction of genetic screening in Singapore's public healthcare system.</p><p>Professor Patrick Tan, Executive Director of PRECISE, said Phase III builds on nearly a decade of precision medicine in Singapore and extends the programme to patients across the public system.</p><h5>Illumina will run sequencing at its Singapore facility under the Healthcare Services Act 2020</h5><p>Illumina's scientific, laboratory and bioinformatics teams will oversee sample preparation, sequencing and genomic data analysis locally. The facility is co-located with the company's manufacturing and R&D operations. It will seek the necessary accreditation and comply with Singapore's Healthcare Services Act 2020 (HCSA).</p><h5>Singapore anchors Illumina's Asia Pacific operations with more than 1,700 employees</h5><p>Illumina established its Singapore presence in 2008. The country now hosts the company's Asia Pacific regional headquarters and is one of its largest hubs outside the United States, with staff across three locations. Operations there cover commercial activity, manufacturing and R&D.</p><p>Illumina CEO Jacob Thaysen said the programme could generate evidence for earlier, more precise intervention. Nilesh Shah, Head of Region for Asia Pacific, said the company remains committed to investing in people, technology and partnerships in Singapore and across the region.</p><p>NPM Phase III is funded by Singapore's Ministry of Health through the NMRC Office at MOH Holdings under the NMRC NPM Phase III Funding Initiative.</p>", "meta_description": "Illumina won an international tender to provide whole-genome sequencing for SG-INSIGHT, covering about 450,000 Singapore residents under NPM Phase III.", "seo_keywords": "Illumina, SG-INSIGHT, whole-genome sequencing, Singapore, precision medicine, National Precision Medicine programme, PRECISE, genomics, Healthcare Services Act", "companies": ["Illumina", "PRECISE"], "industries": ["Healthcare & Biotech"], "markets_regions": ["APAC", "Southeast Asia"], "news_type": ["contract_award", "partnership"], "products": [], "themes": ["precision_medicine", "genomics", "regulatory_compliance"], "events": [], "cta_text": "Learn more about Illumina's genomics and sequencing technologies", "learn_more": "https://illumina.com", "fact_check": {"accuracy_score": 100, "legal_risk": "low", "corrections_made": [], "recommendation": "publish"}}

Content Hash (SHA-256, erste 32 hex)

f004e41ca856d43ec6e6429b969ce7e1

Company Website